1464155-66-5

Upstream product

• 6188-23-4 6-bromoimidazo[1,2-a]pyridine 
• 474706-74-6 6-bromo-3-iodoimidazo[1,2-a]pyridine 
• 126747-14-6 4-cyanophenylboronic acid 

Downstream Products

• 1464155-72-3 4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoic acid 
• 1464151-33-4 4-(6-(4-(morpholine-4-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-34-5 4-(6-(4-(1,4-oxazepane-4-yl)carbonyl)phenylimidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-35-6 4-(6-(4-(4-ethylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464155-74-5 tert-butyl 1-(4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)-4-methylpiperidin-4-ylcarbamate 
• 1464155-77-8 4-(6-(4-(4-amino-4-methylpiperidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-36-7 N-(1-(4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)-4-methylpiperidin-4-yl)acetamide 
• 1464151-37-8 4-(6-(4-(4-(diethylamino)-4-methylpiperidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-38-9 4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2-morpholino-2-oxoethyl)benzamide 
• 1464151-39-0 4-(6-(4-(3-oxopiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-40-3 4-(6-(4-(4-methyl-1,4-diazepane-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464155-80-3 tert-butyl 4-(1-(4-(3-(4-cyanophenyl)imidazo[1,2-a]pyridin-6-yl)benzoyl)piperidin-4-yl)piperazine-1-carboxylate 
• 1464151-41-4 4-(6-(4-(4-(piperazin-1-yl)piperidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 
• 1464151-42-5 4-(6-(4-(1'-methyl-4,4'-bipiperidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE DERIVATIVES

The present invention relates to compounds of general formula (I) wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(O)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases